Ustekinumab for Treating Moderately to Severely Active Crohn’s Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Robert HodgsonMatthew WaltonNerys Woolacott Review Article 30 November 2017 Pages: 387 - 398
Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Hema MistryChidozie NdukaJames Mason Review Article Open access 08 December 2017 Pages: 399 - 406
The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA) Salah GhabriErwan AutinJean Michel Josselin Review Article 15 December 2017 Pages: 407 - 417
A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis Ewa StawowczykPaweł Kawalec Systematic Review Open access 19 December 2017 Pages: 419 - 434
Cost Effectiveness of Treatments for Chronic Constipation: A Systematic Review Dolly HanNicolas IragorriEldon Spackman Systematic Review 19 January 2018 Pages: 435 - 449
Mapping the Paediatric Quality of Life Inventory (PedsQL™) Generic Core Scales onto the Child Health Utility Index–9 Dimension (CHU-9D) Score for Economic Evaluation in Children Tosin LambeEmma FrewOn behalf of the PREDNOS Trial Team Original Research Article 20 December 2017 Pages: 451 - 465
The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011–2017 Chris SkedgelDominika WranikMin Hu Original Research Article Open access 20 January 2018 Pages: 467 - 475
Treatment Preferences in Germany Differ Among Apheresis Patients with Severe Hypercholesterolemia Axel C. MühlbacherAndrew SadlerChristin Juhnke Original Research Article 31 January 2018 Pages: 477 - 493
Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer Josh J. CarlsonKangho SuhWilliam Wong Original Research Article 27 February 2018 Pages: 495 - 504
Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy Amir AnsaripourCarin A. Uyl-de GrootW. Ken Redekop Author Correction 23 February 2018 Pages: 505 - 505
Correction to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology Appraisal Irina A. TikhonovaTracey Jones-HughesMartin Hoyle Correction 24 February 2018 Pages: 507 - 507